Sustainability and Waste Reduction in Single-Use Bioprocessing: Decontamination, Recycling, and the Next Generation of Disposables
How biopharma is addressing the plastic waste problem created by single-use bioprocessing systems.
Sustainability and single-use bioprocessing disposables are the most consequential operational challenges facing biomanufacturing today. Single-use systems transformed contamination control and facility flexibility, but they also introduced a large and growing stream of plastic waste that standard recycling infrastructure was never designed to handle. As environmental, social, and governance (ESG) commitments harden into formal reporting obligations, single-use sector impacts are proving more complex to manage than early adopters anticipated.
Key takeaways
- Single-use bioprocessing components in contact with biological material must be biologically inactivated through autoclave or validated chemical treatment before any recycling pathway becomes viable.
- Life cycle assessment studies show that single-use systems reduce energy demand and global warming potential vs. stainless steel, but generate more solid plastic waste per production campaign.
- Vendor take-back and specialist recycling programs allow decontaminated single-use waste to be converted into secondary materials, diverting it from landfill and incineration.
- Emerging bio-based and recyclable polymer formulations for single-use components are under development, though regulatory validation for direct product-contact materials remains a significant barrier.
- Facilities without measurement systems for single-use waste generation will struggle to produce credible ESG disclosures as reporting requirements tighten.
The decontamination requirement shaping single-use bioprocessing sustainability
The defining constraint distinguishing bioprocessing plastic waste from general lab plastics is the decontamination requirement. Any component in direct contact with a biological agent, cell culture media, or drug product cannot leave a good manufacturing practices (GMP) facility as untreated solid waste. Biological inactivation must be demonstrated under a validated procedure before the material can transition to disposal or recycling.
Autoclave inactivation is the most widely used method. Waste is processed through a cycle qualified for the specific biological agents at the facility, generating GMP documentation that supports the material's disposal or diversion status. For large-volume bag contents where autoclaving is impractical, chemical inactivation using a validated disinfectant at a defined concentration and contact time is applied to the liquid contents before draining, with the inactivated liquid routed through the appropriate chemical waste pathway.
Both approaches carry a downstream consequence for recyclability. Autoclave conditions subject multilayer polymer films and tubing to temperatures that degrade mechanical properties, reducing the material's value for subsequent mechanical recycling. Decontaminated single-use waste therefore requires different infrastructure than the recycling streams used for clean industrial plastics.
Life cycle assessment of single-use vs stainless steel sustainability tradeoffs
Life cycle assessment (LCA) provides a more complete environmental picture than any single metric. Multiple LCA studies comparing single-use and stainless steel monoclonal antibody manufacturing have found that single-use process trains show lower environmental impact than fixed-in-place stainless steel facilities across energy demand, water for injection use, and global warming potential at clinical and commercial scales, primarily because clean-in-place and steam-in-place operations are eliminated.
Solid plastic waste generation is where the environmental balance reverses. Single-use systems produce substantially more solid waste by weight and volume than stainless steel facilities at equivalent scale, because every production campaign generates a new set of bags, tubing, connectors, and filter housings for disposal. The environmental impact depends heavily on the end-of-life pathway: incineration and landfill dominate globally, while energy-recovery incineration captures some embedded energy but recovers no material value. LCA applied to plastic recycling pathways and impacts confirms that end-of-life pathway choice substantially changes overall environmental performance.
Table 1. Comparative environmental profile of single-use and stainless steel bioprocessing platforms across key sustainability indicators.
| Indicator | Single-use systems | Stainless steel systems |
| Energy demand | Lower (no steam-in-place or clean-in-place) | Higher (steam generation, cleaning cycles) |
| Water for injection use | Lower (no equipment washing) | Higher (extensive equipment washing) |
| Global warming potential | Lower across most scale comparisons | Higher across most scale comparisons |
| Solid plastic waste | Higher (disposable components per batch) | Lower (reusable equipment) |
| Changeover time | Lower (no cleaning validation required) | Higher (cleaning validation required) |
| Capital expenditure | Lower upfront | Higher upfront |
These tradeoffs are relevant not only in pharmaceutical manufacturing but also in the broader industrial bioprocessing applications where single-use technology is expanding.
Recycling pathways for decontaminated single-use waste
Specialized recycling infrastructure for biopharma single-use waste has grown in recent years. Major bioprocessing equipment suppliers have established take-back programs that accept decontaminated components and process them through industrial recycling streams, diverting material from landfills. Participation requires decontamination and documentation according to program specifications, typically a certificate of decontamination or validated autoclave records.
The material conversion pathways available include mechanical recycling into secondary polymer pellets for non-medical uses, conversion into plastic lumber and pallets, and energy recovery. Thermoplastic components such as polyethylene and nylon can be melted and reformed into new plastic parts, while thermoset materials such as silicone tubing are processed separately through reclaiming programs for non-critical applications.
The practical limits of take-back programs are logistical: waste must be segregated, inactivated, documented, and shipped to the supplier or its recycling partner. The waste diversion and ESG reporting credit increasingly justify that investment at scale. Facilities without a baseline measurement for single-use waste generation cannot credibly set reduction targets, a gap that process analytics platforms and digital data systems are well positioned to help close.
Emerging materials and the future of single-use bioprocessing sustainability
The next frontier in single-use bioprocessing sustainability is redesigning the components themselves. Current single-use bags and film assemblies are constructed from multilayer polyethylene-based films, chosen for proven biocompatibility and barrier properties but not for end-of-life recyclability. Developing alternatives that meet the same performance and regulatory requirements while enabling better material recovery is an active research priority.
Bio-based and biodegradable polymers, including polyhydroxyalkanoates and polylactic acid, are under active consideration as sustainable substitutes for petroleum-derived plastics in single-use applications. Polyhydroxyalkanoates are microbially produced, fully bio-based, and biodegradable under industrial composting conditions, making them candidates for bioprocessing films if barrier and mechanical performance can be matched to current specifications. Bio-based polymers for circular applications also include bio-polyethylene from renewable feedstocks, which retains the functional properties of conventional polyethylene while reducing fossil carbon content.
Regulatory validation remains the primary barrier to adoption. Any material change affecting a direct product-contact surface requires extractables and leachables characterization against expectations, including USP <665> and <1665>, and in many cases, formal change control and requalification. The Bio-Process Systems Alliance has identified collaborative material development and standardized recyclability testing as industry priorities, recognizing that the regulatory science for alternative materials requires coordination across suppliers, users, and regulators.
Advancing single-use bioprocessing sustainability through procurement and measurement
Sustainability commitments are reshaping how biopharma facilities evaluate single-use systems. Procurement decisions that once centered on performance, price, and supply assurance now increasingly incorporate supplier sustainability credentials: take-back program availability, recycled content, and public ESG reporting. Investor and customer ESG requirements for biopharma companies increasingly include plastic waste reporting, and single-use bioprocessing waste is a significant and growing component of those disclosures.
A waste audit specific to single-use bioprocessing is the essential first step for any facility with credible sustainability goals. Without a quantified baseline, reduction targets are arbitrary, and progress cannot be reported. Facilities with integrated lab data systems are better placed to build the measurement infrastructure that single-use bioprocessing sustainability reporting now requires.
This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
